BC Week In Review | Jun 25, 2012
Clinical News

KBSA301: Phase I/II started

Kenta began a double-blind, placebo-controlled, European Phase I/II trial to evaluate 4 single-doses of IV KBSA301 in combination with standard antibiotic therapy in about 44 intensive care unit (ICU) patients. Kenta Biotech Ltd. , Schlieren, Switzerland...
Items per page:
1 - 1 of 1